Growth impairment and gonadal axis abnormalities are common in survivors of paediatric brain tumours.

Aim: Childhood brain tumour survivors have a high risk of endocrine morbidity. This study evaluated the growth, pubertal development and gonadal function in survivors of childhood brain tumours and identified factors associated with the problems we observed.

Methods: The 52 subjects (52% male) were diagnosed in 1983-1997 and treated for brain tumours at Tampere University Hospital, Finland.

Electroretinography and Visual Evoked Potentials in Childhood Brain Tumor Survivors.

This population-based cross-sectional study evaluates the clinical value of electroretinography and visual evoked potentials in childhood brain tumor survivors. A flash electroretinography and a checkerboard reversal pattern visual evoked potential (or alternatively a flash visual evoked potential) were done for 51 survivors (age 3.8-28.

Neurological outcome of childhood brain tumor survivors.

We assessed neurological and neurocognitive outcome in childhood brain tumor survivors. Altogether, 75 out of 80 brain tumor survivors diagnosed below 17 years between 1983 and 1997; and treated in Tampere University Hospital, Finland, were invited to participate in this population-based cross-sectional study. Fifty-two (69%) participated [mean age 14.

Obesity and metabolic changes are common in young childhood brain tumor survivors.

Background: A population based cross-sectional study was used to examine the prevalence of metabolic syndrome and its components in childhood brain tumor survivors.

Procedure: Fifty-two survivors were examined at a mean age of 14.4 years (range 3.

Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.

Background: This study was designed to evaluate the renal consequences of the treatment of brain tumor patients diagnosed in childhood.

Procedure: One hundred four primary brain tumor patients diagnosed before 17 years of age from 1983 to 1997 had been treated in Tampere University Hospital, Finland. Of the 80 survivors 52 (65.

Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study.

Objective: To assess the efficacy of growth hormone (GH) treatment in severe growth retardation in prepubertal children with juvenile chronic arthritis (JCA).

Methods: In a randomized, double-blind placebo-controlled study, we treated 25 prepubertal children (7 boys, 18 girls, mean age 9.0 yrs) with severe growth retardation due to JCA with human recombinant GH (6 months) and placebo (6 months).

Genetic screening for maternal uniparental disomy of chromosome 7 in prenatal and postnatal growth retardation of unknown cause.

Objective: Many short-statured children lack an etiologic explanation for their retarded growth. Recently, uniparental disomy (UPD), the inheritance of both chromosomes of a chromosome pair from only 1 parent, has been associated with short stature for many chromosomes. Silver-Russell syndrome (SRS) represents an extreme syndrome of intrauterine growth retardation (IUGR) and slight dysmorphic signs, and maternal UPD of human chromosome 7 (matUPD7) has been observed in approximately 10% of SRS cases.